GlassScriptPhysician profile
Sylvia J Rushing
NPI 1578562484
$5,363.44
in general payments reported to CMS, 2019-2025
33 companies · $800 in 2025
The $800 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $809 · 2020: $729 · 2021: $793 · 2022: $714 · 2023: $788 · 2024: $731 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,318.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $956.57 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $671.21 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $492.97 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $420.38 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $385.00 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.80 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $294.13 | 2021-2025 | Verquvo |
| Amgen INC. | $219.65 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $195.87 | 2020-2024 | Confirm Rx, Diamondback Peripheral, Assurity |
| Sanofi-Aventis U.S. LLC | $147.24 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $146.92 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $137.91 | 2023-2024 | Resonate El Icd Vr, Lux-Dx Insertable Cardiac Monitor, Latitude Communicator Power Supply |
| Philips North America LLC | $124.53 | 2020-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| Amarin Pharma, INC. | $118.03 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $114.54 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $104.52 | 2019-2021 | |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Cardiovascular Systems INC. | $68.98 | 2022-2023 | Diamondback Peripheral |
| Kowa Pharmaceuticals America, INC. | $45.89 | 2019-2020 | |
| Irhythm Technologies, INC. | $43.09 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Alnylam Pharmaceuticals INC. | $28.96 | 2025 | Amvuttra |
| Elutia, INC. | $28.33 | 2022-2023 | |
| Esperion Therapeutics, INC. | $26.45 | 2021-2022 | |
| Cardiva Medical, INC. | $22.30 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Bayer Healthcare Pharmaceuticals INC. | $22.28 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $18.33 | 2024 | |
| Ge Healthcare | $17.60 | 2024 | |
| Abiomed | $16.99 | 2024 | Impella |
| Scpharmaceuticals INC. | $16.46 | 2024 | |
| Asahi Intecc USA, INC. | $16.30 | 2025 | Asahi Coronary Wires |
| Lantheus Medical Imaging, INC. | $14.56 | 2022 | |
| Gilead Sciences, INC. | $13.94 | 2019 | |
| Medtronic Vascular, INC. | $12.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Rushing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.